BERKELEY, Calif., June 10, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the company will host a webcast conference call on Thursday, June 17, 2010 at 11:00 a.m. Eastern time to present preliminary results from a clinical trial evaluating XOMA 052 in patients with uveitis of Behcet’s disease. Joining members of XOMA’s management team on the call will be Professor Ahmet Gul, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul University, Turkey, and principal investigator for this XOMA 052 clinical trial. The webcast conference call coincides with Dr. Gul’s presentation on the same day at the annual European Congress of Rheumatology in Rome, Italy, a poster titled, “Safe, Rapid-onset and Sustained Biological Activity of IL-1 beta Regulating Antibody XOMA 052 in Resistant Uveitis of Behcet’s Disease: Preliminary Results of Pilot Trial.”
